Skip to content

An exploratory study on the precise clinical application of anti-tuberculosis drugs

An exploratory study on the precise clinical application of anti-tuberculosis drugs

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050453
Enrollment
Unknown
Registered
2021-08-27
Start date
2021-08-23
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis

Interventions

Intervention Group:Anti tuberculosis treatment

Sponsors

The Third People's Hospital of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily serve as the subject and sign the informed consent; or the guardian agrees that the child will be the subject and sign the informed consent; 2. Aged between 6-75 years, no gender limit, including inpatient and outpatient; 3. Diagnosed with tuberculosis and on anti-tuberculosis drugs for at least one week.

Exclusion criteria

Exclusion criteria: 1. Impaired renal function (serum creatinine exceeding 1.5 times the upper limit of normal), or impaired liver function (ALT and/or AST levels 3 times the upper limit of laboratory reference values); 2. Diabetic patients with poor blood sugar control (HBAc1> 7.0%) and no desire to improve; 3. The QT interval of the electrocardiogram is prolonged by more than 450 milliseconds; 4. Have a history of cardiovascular disease or are suffering from such diseases, such as heart failure, hypertension (poor blood pressure control), arrhythmia or post-myocardial infarction state; 5. According to the judgment of the research team, the subject suffers from any disease that is not suitable for participating in the subject or may prevent the patient from participating in the whole process of the subject (such as severe mental illness, alcoholism, drug use, or other related serious medical conditions affecting treatment, including immunodeficiency).

Design outcomes

Secondary

MeasureTime frame
Relapse rate at 6 months after treatment;

Countries

China

Contacts

Public ContactQu Jiuxin

The Third People's Hospital of Shenzhen

qujiuxin@163.com+86 755 61238937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026